Imprimis to offer low-cost alternative to Restasis
Imprimis Pharmaceuticals will offer a low-cost dry eye treatment intended as an alternative to Allergan’s Restasis, the company announced.
The company will offer the compounded cyclosporine-based formulation in a multi-use, preservative-free bottle, with prescriptions for the patent pending formulation initially filled for 99 cents and refills starting at $79 per month, according to a company press release.
Mark Baum, Imprimis CEO, said in the release, “Topical cyclosporine, which is an off-patent and inexpensive drug, can cost more than $5,000 per year when it is purchased in the commercially available form of Restasis. We believe that affordability can affect access to needed medications, and it is our hope that our formulations will allow more patients to gain access to a high quality customized cyclosporine treatment option.”
In one drug discount program, the cost of Restasis (cyclosporine ophthalmic emulsion 0.05%) is about $170 for 30 emulsions when cash-paying customers apply the discount.